Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Once again. Compare the language to the oringinal July 17, 2012 filing.

.

Today's 8KA

Pursuant to the TPL Agreement, in the event PDS pays delinquent interest to Alliacense under the Program Agreement, TPL’s distributions from PDS will be reduced by the amount that such delinquent interest was in excess of a specified rate. Further, TPL agreed to guarantee certain payments to Alliacense.

8K from July 17,2012

Pursuant to the Program Agreement, PDS has engaged Alliacense to negotiate licenses of certain microprocessor science and design patents (“Patents”) and to pursue claims against violators of the Patents, in each case, on behalf of PDS, TPL, and the Company. The Program Agreement continues through the useful life of the Patents, which is defined as the greater of the period of time when any of the Patents are no longer subject to legal protection or such Patents are reasonably perceived to have commercial value. Pursuant to the TPL Agreement, TPL and the Company agreed to certain allocations of obligations in connection with the engagement of Alliacense.

Share
New Message
Please login to post a reply